PMC:7536913 / 675-1440
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 209-212 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T4 | 214-221 | Disease | denotes | anthrax | http://purl.obolibrary.org/obo/MONDO_0005119 |
| T5 | 258-268 | Disease | denotes | infectious | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T6 | 307-315 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T7 | 375-383 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 562-563 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 600-601 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T6 | 617-618 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T7 | 648-661 | http://purl.obolibrary.org/obo/OBI_0000245 | denotes | organizations |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T3 | 162-173 | Chemical | denotes | application | http://purl.obolibrary.org/obo/CHEBI_33232 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 12 | 214-221 | Species | denotes | anthrax | Tax:1392 |
| 13 | 258-277 | Disease | denotes | infectious diseases | MESH:D003141 |
| 14 | 307-315 | Disease | denotes | COVID‐19 | MESH:C000657245 |
| 15 | 375-383 | Disease | denotes | COVID‐19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 0-96 | Sentence | denotes | Previous public health crises have changed medical product development and regulatory practices. |
| T9 | 97-278 | Sentence | denotes | These examples include major legislative amendments and creative application of regulatory paradigms to address HIV, anthrax and other bioterrorism threats, and infectious diseases. |
| T10 | 279-532 | Sentence | denotes | 1 To address the threat of COVID‐19 and simultaneously ensure continuity of development of non‐COVID‐19 treatments, regulators are providing significant regulatory flexibility while maintaining the high standards for quality, safety, and effectiveness. |
| T11 | 533-765 | Sentence | denotes | As Rasmus Hougaard argued in a recent Forbes article, “The heat of a crisis creates a burning platform, propelling organizations and individuals to make pivots and changes that seemed too hard or overwhelming during normal times.” 2 |